| ［1］ |
Chi W, Kang N, Sheng L, et al. MCT1⁃governed pyruvate metabolism is essential for antibody class⁃switch recombination through H3K27 acetylation［J］. Nat Commun, 2024,15（1）:163. doi: 10.1038/s41467⁃023⁃44540⁃0.
|
| ［2］ |
Dou DR, Zhao Y, Belk JA, et al. Xist ribonucleoproteins promote female sex⁃biased autoimmunity［J］. Cell, 2024,187（3）:733⁃749.e16. doi: 10.1016/j.cell.2023.12.037.
|
| ［3］ |
Wu Z, Zheng Y, Sheng J, et al. CD3（+）CD4（-）CD8（-） （double⁃negative） T cells in inflammation, immune disorders and cancer［J］. Front Immunol, 2022,13:816005. doi: 10.3389/fimmu.2022. 816005.
|
| ［4］ |
Zhang Y, Du L, Wang C, et al. Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis［J］. Signal Transduct Target Ther, 2024,9（1）:18. doi: 10.1038/s41392⁃023⁃01709⁃9.
|
| ［5］ |
Jiang H, Shen Z, Zhuang J, et al. Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy［J］. Front Immunol, 2023,14:1335936. doi: 10.3389/fimmu.2023.1335936.
|
| ［6］ |
Ye B, Chen B, Guo C, et al. C5a⁃C5aR1 axis controls mitochondrial fission to promote podocyte injury in lupus nephritis［J］. Mol Ther, 2024,32（5）:1540⁃1560. doi: 10.1016/j.ymthe.2024.03.003.
|
| ［7］ |
Chen W, Jin B, Cheng C, et al. Single⁃cell profiling reveals kidney CD163（+） dendritic cell participation in human lupus nephritis［J］. Ann Rheum Dis, 2024,83（5）:608⁃623. doi: 10. 1136/ard⁃2023⁃224788.
|
| ［8］ |
Biniaris⁃Georgallis SI, Aschman T, Stergioula K, et al. Amplification of autoimmune organ damage by NKp46⁃activated ILC1s［J］. Nature, 2024,634（8035）:952⁃960. doi: 10.1038/s41586⁃024⁃07907⁃x.
|
| ［9］ |
Ishina IA, Zakharova MY, Kurbatskaia IN, et al. MHC classⅡ presentation in autoimmunity［J］. Cells, 2023,12（2）:314. doi: 10.3390/cells12020314.
|
| ［10］ |
Mori S, Kohyama M, Yasumizu Y, et al. Neoself⁃antigens are the primary target for autoreactive T cells in human lupus［J］. Cell, 2024,187（21）:6071⁃6087.e20. doi: 10.1016/j.cell.2024.08.025.
|
| ［11］ |
Tian J, Shi L, Zhang D, et al. Dysregulation in keratinocytes drives systemic lupus erythematosus onset［J］. Cell Mol Immunol, 2025,22（1）:83⁃96. doi: 10.1038/s41423⁃024⁃01240⁃z.
|
| ［12］ |
Hiraoka D, Ishizaki J, Yamanouchi J, et al. Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus⁃formation analysis system （T⁃TAS）［J］. Lupus Sci Med, 2024,11（2）:e001223. doi: 10.1136/lupus⁃2024⁃001223.
|
| ［13］ |
Doglio M, Alexander T, Del Papa N, et al. New insights in systemic lupus erythematosus: from regulatory T cells to CAR⁃T⁃cell strategies［J］. J Allergy Clin Immunol, 2022,150（6）:1289⁃1301. doi: 10.1016/j.jaci.2022.08.003.
|
| ［14］ |
Doglio M, Ugolini A, Bercher⁃Brayer C, et al. Regulatory T cells expressing CD19⁃targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus［J］. Nat Commun, 2024,15（1）:2542. doi: 10.1038/s41467⁃024⁃46448⁃9.
|
| ［15］ |
Rovin BH, Furie RA, Ross Terres JA, et al. Kidney outcomes and preservation of kidney function with obinutuzumab in patients with lupus nephritis: a post hoc analysis of the NOBILITY trial［J］. Arthritis Rheumatol, 2024,76（2）:247⁃254. doi: 10.1002/art.42734.
|
| ［16］ |
Wang W, He S, Zhang W, et al. BCMA⁃CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open⁃label clinical trial［J］. Ann Rheum Dis, 2024,83（10）:1304⁃1314. doi: 10.1136/ard⁃2024⁃225785.
|
| ［17］ |
Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma［J］. N Engl J Med, 2022,387（6）:495⁃505. doi: 10.1056/NEJMoa2203478.
|
| ［18］ |
Alexander T, Krönke J, Cheng Q, et al. Teclistamab⁃induced remission in refractory systemic lupus erythematosus［J］. N Engl J Med, 2024,391（9）:864⁃866. doi: 10.1056/NEJMc2407150.
|
| ［19］ |
Strasser DS, Froidevaux S, Sippel V, et al. Preclinical to clinical translation of cenerimod, a novel S1P（1） receptor modulator, in systemic lupus erythematosus［J］. RMD Open, 2020,6（2）:e001261. doi: 10.1136/rmdopen⁃2020⁃001261.
|
| ［20］ |
Mueller MS, Juif PE, Charfi H, et al. Multiple⁃dose pharmacokinetics of cenerimod and the effect of charcoal on its elimination［J］. J Clin Pharmacol, 2024,64（12）:1566⁃1575. doi: 10.1002/jcph.6106.
|
| ［21］ |
Cai T, Lenoir Capello R, Pi X, et al. Structural basis of γ chain family receptor sharing at the membrane level［J］. Science, 2023,381（6657）:569⁃576. doi: 10.1126/science.add1219.
|
| ［22］ |
Yin H, Li L, Feng X, et al. 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus［J］. Signal Transduct Target Ther, 2024,9（1）:323. doi: 10.1038/s41392⁃024⁃02017⁃6.
|
